Epinex Diagnostics Inc. (click on preceding link for the Company's News Room page) is a private company that is dedicated to the development of innovative point-of-care technologies using rapid diagnostic tests. Epinex has developed a proprietary platform for rapid tests that apply existing immunoassay strips and biosensors to create unique quantitative diagnostic test.
Advantages of the Epinex Quantitative Immunoassay System for Point-of-Care Testing include the following:
1.) Rapid: Results within minutes.
2.) Quantitative: Yields a precise value, not just "yes" or "no".
3.) Easy to use: No training required.
4.) Cost effective: Point-of-care testing reduces overall cost to the healthcare system.
5.) High Sensitivity: Results comparable to the "gold standard" ELISA test.
The Epinex G1ATM (glycated albumin, which is a measure of average blood sugar control over the previous month) Test is the first of a series of diagnostic monitoring tests based on the Company's proprietary detection platform technology and dual-mode test reader. Future rapid tests under development by Epinex include infectious diseases, other metabolic disorders, coronary artery disease, rheumatoid arthritis, Down Syndrome, and neonatal HIV.
Albumin is a protein found in the blood that can be measured with precision and has a turnover or replacement time of 2-3 weeks. Like many proteins in the body, albumin can become altered or glycated. High levels of glycated albumin have been directly linked to major complications of diabetes such as retinopathy (blindness) and nephropathy (kidney failure) through the damage caused to small blood vessels by the altered protein. It is also a marker for other types of diabetes complications.
